Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 16Colonic Neoplasms 11Rectal Neoplasms 8Head and Neck Neoplasms 7Neoplasm Metastasis 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Chordoma 2Breast Neoplasms 2Unresectable Colorectal Cancer 1Tongue Neoplasms 1Thymoma 1Solid Tumor, Adult 1Solid Cancer 1Skin Neoplasms 1Rectal Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Noonan Syndrome 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1

Interventions

Surveys and Questionnaires 1Mitomycin 1Leucovorin 1Lansoprazole 1Hyperthermic Intraperitoneal Chemotherapy 1Floxuridine 1Cytoreduction Surgical Procedures 1Clarithromycin 1Cetuximab 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Appendiceal Neoplasms × Cetuximab × Clear all
NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
48 enrolled
Gastrointestinal

Appendiceal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡